N@N

GAITHERSBURG, Md.--([ BUSINESS WIRE ])--AccelPath, Inc. (OTCBB: ACLP) (aAccelPatha or the aCompanya) announced today that Dr. Keith J. Kaplan, M.D. continues his role as Chairman and active member of the Companyas Medical Advisory Board.

"We are very pleased with our collaborative relationship with Dr. Kaplan"

Keith J. Kaplan, MD is a pathologist and Chief Information Officer (CIO) of Carolinas Pathology Group (CPG), Celligent Diagnostics and Diligent Billing and Management. As CIO, Dr. Kaplan is responsible for all aspects of informatics strategies, operations, and projects and processes that encompass laboratory, healthcare and research information systems for Carolinas Pathology Group. Prior to joining CPG, Dr. Kaplan was a surgical pathologist at Mayo Clinic, Rochester, Minnesota and also held the academic post of associate professor of pathology of Mayo Medical School.

Dr. Kaplan is a graduate of Michigan State University, a graduate of Northwestern University Feinberg School of Medicine and completed residency training in anatomic and clinical pathology at Walter Reed Army Medical Center, Washington, DC. While at Walter Reed, Dr. Kaplan was named Resident of the Year and, in conjunction with the Armed Forces Institute of Pathology, Dr. Kaplan founded and directed the Army Telepathology Program. This Program connected 25 hospitals internationally for consultation via telepathology. Dr. Kaplan also served as the Medical Director and Consulting Pathologist of Laboratory Services at Keller Army Hospital in West Point, New York.

Dr. Kaplan is board certified in anatomic and clinical pathology. His subspecialty interests include gastrointestinal and hepatic pathology, cytopathology and pathology informatics as well as research interests in gastrointestinal and hepatobiliary pathology, hyperspectral imaging, image analysis and the use of Web 2.0 tools in pathology. He has authored over 60 peer-reviewed scientific articles, book chapters, editorials and scientific abstracts and frequently lectures at both national and international meetings on topics related to pathology informatics.

Dr. Kaplan currently serves as a member of the College of American Pathologists, American Society of Clinical Pathology and the American Society of Cytopathology as well as the American Pathology Foundation. He is also an executive board member of the Digital Pathology Association. Dr. Kaplan has previously served as a member of the College of American Pathologists Informatics Committee, Standards Committee, and Instrumentation Resource Committee and as co-chair of the American Telemedicine Association Telepathology Special Interest Group.

aWe are very pleased with our collaborative relationship with Dr. Kaplan,a stated Shekhar Wadekar, AccelPathas Chairman and Chief Executive Officer. aDr. Kaplanas expertise in the technical and medical components of digital telepathology (through his experiences at Walter Reed Army Medical Center / the Armed Forces Institute of Pathology, founding and directing the Army Telepathology Program, and industry experience as a practicing pathologist) provides us significant insights while we enhance our proprietary digital telepathology solutions. He will also be invaluable as we further apply those to existing pathology laboratories and related service providers.a

About AccelPath

AccelPath provides technology solutions that play a key role in delivering information required for diagnosis of diseases and other pathologic conditions with and through its associated institutional pathologists. The medical institutions, with whom the Company partners, prepare comprehensive diagnostic reports of a patientas condition and consult with referring physicians to help determine the most appropriate treatment. Such diagnostic reports enable the early detection of disease, allowing referring physicians to make informed and timely treatment decisions that improve their patientsa health in a cost-effective manner. The Company seeks out referring physicians and histology laboratories in need of high-quality pathology interpretations and manages HIPAA-compliant digital case delivery and reporting while developing comprehensive solutions for managing medical information.

AccelPath is currently focused on the $14 billion anatomic pathology market in the US. The Companyas business model builds upon the expertise of experienced pathologists to provide seamless, reliable and comprehensive pathology and special test offerings to referring physicians using conventional and digital technologies.The Company establishes longstanding relationships with the referring physicians as a result of focused delivery of its partneras diagnostic services, personalized responses and frequent consultations, and its proprietary flexible information technology, or IT, solutions that are customizable to the referring physiciansa or laboratories as well as the pathologistsa needs. Such diagnostic reports often enable the early detection of disease, allowing referring physicians to make informed and timely treatment decisions that improve their patientsa health in a cost-effective manner. AccelPathas IT and communications platform enables it to efficiently and securely deliver diagnostic reports to referring physicians. In addition, AccelPathas IT platform enables close tracking and monitoring of medical statistics.

AccelPath is focused on the design, research, development and integration of three-dimensional imaging devices and systems primarily in the healthcare industries which it contributes to the Company. The Company will also exploit its three-dimensional imaging technology for use in intelligent surveillance devices and systems, as well as three-dimensional facial recognition systems for security and law enforcement agencies thru future strategic partnerships. Historically, the Companyas largest customers have been the National Institutes of Health and the Department of Defense.

Additional Company information may be found on the Internet at:

[ www.accelpath.com ].

Forward-Looking Statements

This press release contains certain aforward-looking statementsa relating to the business of the Company, which can be identified by the use of forward-looking terminology such as amay,a awill,a aexpect,a aanticipate,a aintend,a aestimate,a abelieve,a aproject,a acontinue,a aplan,a aforecast,a or other similar words, or the negative thereof, unless the context requires otherwise. These statements include, but are not limited to, statements about the Companyas current discussions with scanner manufacturers, the Companyas expected future performance and the acceptance of the Companyas product offerings. The results anticipated by any or all of these forward-looking statements may not occur. In addition, these statements reflect managementas current views with respect to future events and are subject to numerous risks, uncertainties and other factors that could cause actual results to differ materially from those set forth in or implied by these forward-looking statements. Factors that could affect those results include, but are not limited to, our ability to conclude our discussions with these manufacturers on favorable terms, the acceptance of our solutions in the marketplace, the efforts of our sales force, general economic conditions, and those described in the Companyas reports on Forms 8-K, 10-Q and 10-K and proxy statements and information statements including amendments, which have been or will be filed by the Company with the Securities and Exchange Commission (the aSECa), including without limitation under the caption aRisk Factorsa in the Company's Annual Report on Form 10-K filed on October 13, 2011. Many of the factors that will determine the outcome of the subject matter of this press release are beyond the Companyas ability to control or predict. The Company undertakes no obligation and expressly disclaim any obligation, to revise or publicly update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.